Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, announced it will provide business updates and report third-quarter financial results on November 7, 2022, at 8:00 a.m. ET. A conference call will be held, accessible via dial-in or live webcast on the company’s website. Mersana specializes in antibody-drug conjugates (ADCs) aimed at addressing high unmet needs in cancer treatment, with key candidates like upifitamab rilsodotin (UpRi) in pivotal trials for ovarian cancer. The company is also developing other ADCs and has collaborations underway.

CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the third quarter ended September 30, 2022 on Monday, November 7, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) and provide the Conference ID 9941053. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics report its third-quarter financial results for 2022?

Mersana Therapeutics will report its third-quarter financial results on November 7, 2022.

What time is the conference call for Mersana Therapeutics' Q3 results?

The conference call for Mersana Therapeutics' Q3 results is scheduled for 8:00 a.m. Eastern Time.

How can I access the Mersana Therapeutics conference call?

You can access the Mersana Therapeutics conference call by dialing 646-307-1963 (domestic) or 800-715-9871 (international) and using Conference ID 9941053.

What is Mersana Therapeutics' lead product candidate?

Mersana Therapeutics' lead product candidate is upifitamab rilsodotin (UpRi), targeting NaPi2b in ovarian cancer.

What trials are being conducted for upifitamab rilsodotin?

Upifitamab rilsodotin is involved in the UPLIFT, UPGRADE, and UP-NEXT trials for different ovarian cancer treatment strategies.